Logo

Oxford Genome Sciences, Amgen To Collaborate on Cancer Antibodies

Dec 26, 2007
NEW YORK (GenomeWeb News) - Oxford Genome Sciences said last weekthat it is collaborating with Amgen to discover, develop, and commercialize therapeutic antibodies for cancer.
 
The companies will use Amgen’s XenoMouse technology to generate fully human anibodies, which will be raised against druggable targets that Oxford Genome Sciences has identified through its Oxford Genome Anatomy Project database of cancer proteins.
 
The agreement covers up to six oncology programs. Amgen has the right to select up to three programs while Oxford Genome Sciences retains the rights to the rest. After Amgen has produced the initial antibody leads, Oxford Genome will carry out the initial pre-clinical assessment of each antibody program.
 
Further terms of the deal were not disclosed.

Breaking News
The Scan

Wolf Howl Responses Offer Look at Vocal Behavior-Related Selection in Dogs

In dozens of domestic dogs listening to wolf vocalizations, researchers in Communication Biology see responses varying with age, sex, reproductive status, and a breed's evolutionary distance from wolves.

Facial Imaging-Based Genetic Diagnoses Appears to Get Boost With Three-Dimensional Approach

With data for more than 1,900 individuals affected by a range of genetic conditions, researchers compared facial phenotype-based diagnoses informed by 2D or 3D images in the European Journal of Human Genetics.

Survey Suggests Multigene Cancer Panel VUS Reporting May Vary Across Genetic Counselors

Investigators surveyed dozens of genetic counselors working in clinical or laboratory settings, uncovering attitudes around VUS reporting after multigene cancer panel testing in the Journal of Genetic Counseling.

Study Points to Tuberculosis Protection by Gaucher Disease Mutation

A mutation linked to Gaucher disease in the Ashkenazi Jewish population appears to boost Mycobacterium tuberculosis resistance in a zebrafish model of the lysosomal storage condition, a new PNAS study finds.